EDX Medical Group PLC - Cambridge, England-based firm that develops digital diagnostic products and services to treat cancer, heart disease, and infectious diseases - Signs master services agreement with Royal Marsden NHS Foundation Trust. The agreement will see EDX supply services to Royal Marsden over a three-year period. EDX Medical Founder & Chief Scientific Officer Chris Evans comments: "I am delighted EDX Medical has now been appointed as a supplier of diagnostic solutions and services to help serve the needs of one of the world's most eminent cancer hospitals."
Current stock price: 12.75 pence
12-month change: up 24%
By Christopher Ward, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2025 Alliance News Ltd. All Rights Reserved.